Progress continues apace with multiple trials expected to enter clinic later this year First US patent granted LONDON, July 15, 2022 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, has today published its financial results for the quarter…

Source

Previous articleFILAMENT HEALTH ANNOUNCES CLOSING OF $2,500,080 PRIVATE PLACEMENT
Next articleGeorge Tziras to Succeed Peter Rands as Small Pharma Chief Executive Officer